Berenberg Bank reaffirmed their buy rating on shares of Eli Lilly and Company (NYSE:LLY) in a report issued on Thursday morning. They currently have a $100.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. TheStreet raised shares of Eli Lilly and from a c+ rating to a b+ rating in a research note on Tuesday, July 25th. Piper Jaffray Companies reissued a buy rating and issued a $100.00 target price on shares of Eli Lilly and in a research note on Monday, April 17th. Citigroup Inc. raised their target price on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a buy rating in a research note on Wednesday, April 19th. Zacks Investment Research raised shares of Eli Lilly and from a hold rating to a buy rating and set a $94.00 target price on the stock in a research note on Tuesday, April 4th. Finally, Jefferies Group LLC reissued a buy rating and issued a $97.00 target price on shares of Eli Lilly and in a research note on Monday, April 10th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of Hold and a consensus target price of $88.37.

Eli Lilly and (LLY) traded down 0.2415% during trading on Thursday, hitting $82.8993. 2,203,713 shares of the company’s stock traded hands. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The firm’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.37. The stock has a market cap of $87.63 billion, a P/E ratio of 35.8716 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.50%. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the firm posted $0.86 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Analysts anticipate that Eli Lilly and will post $4.15 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/eli-lilly-and-company-nyselly-given-buy-rating-at-berenberg-bank/1464286.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the completion of the transaction, the insider now directly owns 124,475,804 shares of the company’s stock, valued at approximately $10,337,715,522.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of LLY. Joel Isaacson & Co. LLC raised its position in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the period. Nisa Investment Advisors LLC raised its position in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the period. Franklin Street Advisors Inc. NC acquired a new position in Eli Lilly and during the first quarter valued at approximately $320,000. Washington Trust Bank raised its position in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the period. Finally, Bollard Group LLC raised its position in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the period. 75.48% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.